Literature DB >> 26225870

A systematic review and meta-analysis on outcomes after Rx or R1 endoscopic resection of superficial gastric cancer.

Pedro C Figueiredo1, Pedro Pimentel-Nunes, Diogo Libânio, Mário Dinis-Ribeiro.   

Abstract

OBJECTIVE: Endoscopic resection is a standard treatment for gastric superficial lesions. A positive or a nonevaluable margin is considered a noncurative criterion. We aimed to systematically review recurrence, residual disease, lymph node metastasis (LNM) and cancer-related death following Rx/R1 resection of gastric lesions in the absence of other noncurative criteria.
MATERIALS AND METHODS: MEDLINE systematic review and meta-analysis by July 2014.
RESULTS: Data were extracted from 31 manuscripts. Definitions and results differed significantly. However, nonevaluable (HMx) and positive horizontal margins (HM1) were associated with 10% [95% confidence interval (CI) 5-15%] and 36% (95% CI 24-48%) rates of recurrence/residual disease, respectively, with an odds ratio of 2.85 (95% CI 1.6-5.8, P<0.01) for HM1 compared with HMx. Nonevaluable (VMx) or positive (VM1) vertical margin was associated with a 43% (95% CI 17-68%) rate of recurrence/residual. VMx/VM1 was associated with a higher risk of recurrence/residual compared with HMx/HM1 (odds ratio 3.76, 95% CI 1.71-6.82, P<0.01). The most common strategy after HMx/HM1 was endoscopic surveillance and retreatment, whereas surgery was recommended after VMx/VM1. No cases of LNM or cancer-related death were noticeable if neither submucosal invasion more than 500 µm nor lymphovascular infiltration was also reported.
CONCLUSION: Rx/R1 resection in the absence of other noncurative criteria does not appear to be a significant risk factor for LNM or cancer-related death. The risk of recurrence/residual disease is higher after HM1 than HMx and higher after VMx/VM1 than HMx/HM1. However, considerable heterogeneity was found in studies. Standard definitions should be created and applied in future studies.

Entities:  

Mesh:

Year:  2015        PMID: 26225870     DOI: 10.1097/MEG.0000000000000440

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  3 in total

1.  Clinical Management after Endoscopic Submucosal Dissection for Early Gastric Cancer: Sticking to the Gastroenterologist May Be the Best Option!

Authors:  Pedro Barreiro; Miguel Bispo
Journal:  GE Port J Gastroenterol       Date:  2016-12-16

Review 2.  Evaluation and Management of Gastric Superficial Neoplastic Lesions.

Authors:  Pedro Pimentel-Nunes; Diogo Libânio; Mário Dinis-Ribeiro
Journal:  GE Port J Gastroenterol       Date:  2016-11-01

3.  Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.

Authors:  Haiping Jiang; Xiongfei Yu; Ning Li; Mei Kong; Zhimin Ma; Donghui Zhou; Weibin Wang; Haohao Wang; Haiyong Wang; Kuifeng He; Zhongqi Li; Yimin Lu; Jing Zhang; Kui Zhao; Yafei Zhang; Nong Xu; Ziran Li; Ying Liu; Yan Wang; Yisen Wang; Lisong Teng
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.